FMP

FMP

Enter

NBTX - Nanobiotix S.A.

photo-url-https://images.financialmodelingprep.com/symbol/NBTX.png

Nanobiotix S.A.

NBTX

NASDAQ

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. The company was incorporated in 2003 and is headquartered in Paris, France.

3.34 USD

0.031 (0.928%)

NBTX Financial Statements

Quarter

2024 Q2

2023 Q4

2023 Q2

2022 Q4

Total Revenue

9.29M

32.91M

3.29M

1.72M

Cost of Revenue

0

0

0

754k

Gross Profit

9.29M

32.91M

3.29M

969.5k

Operating Expenses

32.94M

34.32M

28.66M

23.49M

Research and Development

21.99M

20.59M

17.8M

15.53M

Selling, General & Administrative Expenses

10.83M

11.19M

10.86M

7.98M

Selling & Marketing Expenses

0

0

0

0

General & Administrative Expenses

0

0

0

0

Other Expenses

121k

2.55M

-6k

25k

Operating Income

-23.65M

-1.41M

-25.37M

-24.25M

Total Other Income/Expenses Net

1.92M

-10.07M

-2.73M

-4.93M

Income Before Tax

-21.73M

-11.48M

-28.1M

-33.72M

Income Tax

144k

117k

3k

-3.03M

Net Income

-21.87M

-11.6M

-28.1M

-30.68M

Basic EPS

-0.46

-0.3

-0.8

-0.88

EPS Diluted

-0.46

-0.31

-0.8

-0.88

Basic Average Shares

47.12M

37.99M

35.04M

34.85M

Diluted Average Shares

47.12M

38.82M

35.04M

34.85M

EBITDA

-23.24M

1.41M

-24.64M

-10.26M

Retained Earning Schedule

Quarter

2024 Q2

2023 Q4

2023 Q2

2022 Q4

Retained Earnings (Previous Year)

-336.45M

-39.7M

-28.1M

-57.04M

Net Income

-21.87M

-11.6M

-28.1M

-30.68M

Stock Repurchases

0

0

0

0

Dividend Paid

0

0

0

0

Retained Earnings

-68.13M

-336.45M

-39.7M

-28.1M

Other Distributions

268.32M

-296.75M

-11.6M

28.94M

PPE Schedule

Quarter

2024 Q2

2023 Q4

2023 Q2

2022 Q4

Gross PPE

5.54M

5.75M

6.25M

6.48M

Annual Depreciation

287k

274k

741k

754k

Capital Expenditure

-489k

-5k

-324k

-14k

Net PPE

5.74M

5.48M

5.83M

5.74M

Intangible and Goodwill Schedule

Quarter

2024 Q2

2023 Q4

2023 Q2

2022 Q4

Acquisitions and Adjustments

0

0

0

0

Goodwill (Previous Year)

0

0

0

0

Goodwill

0

0

0

0

All figures are in EUR.

FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedin
2017-2025 © Financial Modeling Prep